Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-122A plus standard of care for ventilator-associated pneumonia
NL-OMON60171Phase 2Not yet recruiting
- Sponsor
- TechnoPhage
- Start
- Mar 2026
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in ventilator-associated pneumonia (VAP) comparing TP-122A + standard of care with Standard of care alone (2 arms). Primary endpoints: Adverse events, Clinical laboratory parameters and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
TP-122A
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NL-OMON60171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60171.